GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Statera BioPharma Inc (STU:7CB) » Definitions » Debt-to-Revenue

Statera BioPharma (STU:7CB) Debt-to-Revenue : N/A (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Statera BioPharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Statera BioPharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was €6.79 Mil. Statera BioPharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was €0.69 Mil. Statera BioPharma's annualized Revenue for the quarter that ended in Sep. 2022 was €0.00 Mil.


Statera BioPharma Debt-to-Revenue Historical Data

The historical data trend for Statera BioPharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Statera BioPharma Debt-to-Revenue Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Debt-to-Revenue
N/A N/A N/A

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Statera BioPharma's Debt-to-Revenue

For the Biotechnology subindustry, Statera BioPharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Statera BioPharma's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's Debt-to-Revenue falls into.



Statera BioPharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Statera BioPharma's Debt-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(4.275 + 10.116) / N/A
=N/A

Statera BioPharma's annualized Debt-to-Revenue for the quarter that ended in Sep. 2022 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(6.787 + 0.693) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2022) Revenue data.


Statera BioPharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Statera BioPharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Statera BioPharma (STU:7CB) Business Description

Traded in Other Exchanges
N/A
Address
4333 Corbett Drive, Suite 1082, Fort Collins, CO, USA, 80525
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.

Statera BioPharma (STU:7CB) Headlines

No Headlines